Viropharma Inc Revenue Growth Rates (VPHM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Viropharma Inc  (VPHM)
 

VPHM's Revenue Growth by Quarter and Year

Viropharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VPHM Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December -
3rd Quarter September 113.06
2nd Quarter June 103.71
1st Quarter March 0.00
FY 216.77





VPHM Revenue third quarter 2013 Y/Y Growth Comment
Viropharma Inc showed record Revenue growth in the third quarter 2013 with 24.24% from the third quarter 2013 2012, to $ 113.06 millions.

Looking into third quarter 2013 results within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Revenue growth. While Viropharma Inc' s Revenue rise of 24.24% ranks overall at the positon no. 785 in the third quarter 2013.


VPHM Revenue ( Y/Y Growth %) 2013
 2012 2011 2010
4th Quarter December - - - -
3rd Quarter September 24.24 % - - -
2nd Quarter June 9.58 % - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Viropharma Inc's third quarter 2013 Revenue $ 113.06 millions VPHM's Income Statement
Viropharma Inc's third quarter 2012 Revenue $ 91.00 millions Quarterly VPHM's Income Statement


VPHM Revenue (Quarter on Quarter Growth %)

 2013
 2012 2011 2010
4th Quarter December - 166.25 % - -
3rd Quarter September 9.02 % -3.85 % - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to VPHM Growth rate Comparisons >> Back to VPHM Growth rate Comparisons >>


Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #128
Overall #785

Revenue Y/Y Growth Statistics
High Average Low
24.24 % 16.91 % 9.59 %
(Sep 30 2013)   (Jun 30 2013)
Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #128
Overall #785
Revenue Y/Y Growth Statistics
High Average Low
24.24 % 16.91 % 9.59 %
(Sep 30 2013)   (Jun 30 2013)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Viropharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
166.24 % 57.14 % -3.84 %
(Dec 31 2012)  


VPHM's III. Quarter Q/Q Revenue Comment
Viropharma Inc achieved in the III. Quarter 2013 below company average Revenue increase of 9.02% quarter on quarter, to $ 113.06 millions.

Although the III. Quarter 2013 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -3.85% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Viropharma Inc's Revenue growth quarter on quarter, overall rank is 735.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #111
Overall #735
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #111
Overall #735
Revenue Q/Q Growth Statistics
High Average Low
166.24 % 57.14 % -3.84 %
(Dec 31 2012)  


VPHM's III. Quarter Q/Q Revenue Comment
Viropharma Inc achieved in the III. Quarter 2013 below company average Revenue increase of 9.02% quarter on quarter, to $ 113.06 millions.

III. Quarter 2013 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -3.85% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Viropharma Inc's Revenue growth quarter on quarter, overall rank is 735.


Viropharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2013)		 12 Months Ending
(Jun 30 2013)		 12 Months Ending
(Mar 31 2013)		 12 Months Ending
(Dec 31 2012)		 12 Months Ending
(Sep 30 2012)
Cumulative Revenue 12 Months Ending $ 550.07 $ 531.64 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 3.47 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 490 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Viropharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 24.24% year on year, to $ 550 millions if the fiscal year would have ended in Sep 30 2013.
Viropharma Inc's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2013. And, Viropharma Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Jun 30 2013 rise was beneth at 3.47 % from $531.64 millions achieved in the period from Jun 30 2013 to Sep 30 2012.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Viropharma Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 42
S&P 500 # 490
Cumulative Revenue growth Comment
Viropharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 24.24% year on year, to $ 550 millions if the fiscal year would have ended in Sep 30 2013.
Viropharma Inc's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2013. And, Viropharma Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Jun 30 2013 rise was beneth at 3.47 % from $531.64 millions achieved in the period from Jun 30 2013 to Sep 30 2012.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Jun 30 2013 exhibited at 3.47 % increase from $531.64 millions in the period from Jun 30 2013 to Sep 30 2012.

Viropharma Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 42
S&P 500 # 490




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VPHM's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2013
Seagen Inc 42.42%$ 42.417 millions
Incyte Corporation40.72%$ 40.718 millions
International Stem Cell Corporation40.69%$ 40.691 millions
Regeneron Pharmaceuticals Inc 39.59%$ 39.594 millions
Nanostring Technologies Inc 39.01%$ 39.006 millions
Escalon Medical Corp 37.91%$ 37.915 millions
Vyant Bio Inc 37.22%$ 37.224 millions
Musclepharm Corporation36.45%$ 36.451 millions
Alexion Pharmaceuticals Inc 36.13%$ 36.129 millions
Chemocentryx Inc.34.93%$ 34.929 millions
Emergent Biosolutions Inc 33.80%$ 33.803 millions
Savient Pharmaceuticals Inc33.58%$ 33.584 millions
Vaso Corporation32.93%$ 32.926 millions
Jazz Pharmaceuticals Plc32.27%$ 32.274 millions
Biogen Inc 31.92%$ 31.917 millions
Sanara Medtech Inc 31.26%$ 31.260 millions
Cambrex Corp30.81%$ 30.809 millions
Lannett Company Inc29.85%$ 29.849 millions
Lifeloc Technologies Inc 29.45%$ 29.450 millions
Biolife Solutions Inc 29.08%$ 29.082 millions
Emeritus Corpwa29.02%$ 29.023 millions
Biospecifics Technologies Corp28.47%$ 28.465 millions
Pacific Health Care Organization Inc28.40%$ 28.399 millions
Cardiovascular Systems Inc 27.79%$ 27.789 millions
Cerus Corporation27.75%$ 27.751 millions
Reflect Scientific Inc27.43%$ 27.427 millions
Medicines Co27.41%$ 27.412 millions
Macrogenics Inc 25.81%$ 25.810 millions
Atricure Inc 24.83%$ 24.828 millions
Illumina Inc 24.81%$ 24.810 millions


About Viropharma Inc Revenue Growth Rates (VPHM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.